Tag: progestin

Articles

• Birth control pill use and breast cancer
• Breast density and breast cancer risk and recurrence
• Hormone replacement therapy (HRT) and breast cancer

News

11/06/11

Combination HRT doubles BC risk among women with breast tenderness

05/10/11

Apigenin may prevent BC that develops in response to progestin

07/29/10

HRT increases risk of BC, especially for those with dense breasts

Studies

• Abstract SS02-02: Hormone Replacement and Alternatives for Relief of Vasomotor Symptoms in Women at Increased Risk for Breast Cancer Cite
  Fabian C. Abstract SS02-02: Hormone Replacement and Alternatives for Relief of Vasomotor Symptoms in Women at Increased Risk for Breast Cancer. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:SS02-02-SS02-02 10.1158/1538-7445.sabcs23-ss02-02
• Antiprogestins for breast cancer treatment: we are almost ready Cite
  Elia A, Pataccini G, Saldain L, Ambrosio L, Lanari C, Rojas P. Antiprogestins for breast cancer treatment: we are almost ready. The Journal of Steroid Biochemistry and Molecular Biology. Elsevier BV; 2024;:106515 10.1016/j.jsbmb.2024.106515
• Navigating a plethora of progesterone receptors: Comments on the safety/risk of progesterone supplementation in women with a history of breast cancer or at high-risk for developing breast cancer Cite
  Diep CH, Mauro LJ, Lange CA. Navigating a plethora of progesterone receptors: Comments on the safety/risk of progesterone supplementation in women with a history of breast cancer or at high-risk for developing breast cancer. Steroids. Elsevier BV; 2023; 200:109329 10.1016/j.steroids.2023.109329
• Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case–control study and meta-analysis Cite
  Fitzpatrick D, Pirie K, Reeves G, Green J, Beral V. Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case–control study and meta-analysis. PLOS Medicine. Public Library of Science (PLoS); 2023; 20:e1004188 10.1371/journal.pmed.1004188
• Kaempferol, a Phytoprogestin, Induces a Subset of Progesterone-Regulated Genes in the Uterus Cite
  Bergsten TM, Li K, Lantvit DD, Murphy BT, Burdette JE. Kaempferol, a Phytoprogestin, Induces a Subset of Progesterone-Regulated Genes in the Uterus. Nutrients. MDPI AG; 2023; 15:1407 10.3390/nu15061407
• Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study Cite
  Burchardt NA, Eliassen AH, Shafrir AL, Rosner B, Tamimi R, Kaaks R, et al. Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study. American Journal of Obstetrics and Gynecology. Elsevier BV; 2021; 10.1016/j.ajog.2021.12.022
• Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation Cite
  Shamseddin M, De Martino F, Constantin C, Scabia V, Lancelot A, Laszlo C, et al. Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation. EMBO Molecular Medicine. EMBO; 2021; 10.15252/emmm.202114314
• Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials Cite
  Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA. American Medical Association (AMA); 2020; 324:369 10.1001/jama.2020.9482
• Abstract GS5-00: Long-term influence of estrogen plus progestin and estrogen alone use on breast cancer incidence: The Women's Health Initiative randomized trials Cite
  Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick M, Pan K, et al. Abstract GS5-00: Long-term influence of estrogen plus progestin and estrogen alone use on breast cancer incidence: The Women's Health Initiative randomized trials. General Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-gs5-00
• Different menopausal hormone regimens and risk of breast cancer Cite
  Brusselaers N, Tamimi R, Konings P, Rosner B, Adami H, Lagergren J. Different menopausal hormone regimens and risk of breast cancer. Annals of Oncology. Elsevier BV; 2018; 29:1771-1776 10.1093/annonc/mdy212
• Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian Women and Cancer Study Cite
  Busund M, Bugge NS, Braaten T, Waaseth M, Rylander C, Lund E. Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian Women and Cancer Study. International Journal of Cancer. Wiley; 2018; 142:2293-2302 10.1002/ijc.31266
• Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro Cite
  Goyette S, Liang Y, Mafuvadze B, Cook M, Munir M, Hyder S. Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro. Breast Cancer: Targets and Therapy. Informa UK Limited; 2017; Volume 9:347-357 10.2147/bctt.s135371
• Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk Cite
  Byrne C, Ursin G, Martin CF, Peck JD, Cole EB, Zeng D, et al. Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2017; 109 10.1093/jnci/djx001
• Estrogen–progestin use and breast cancer characteristics in lean and overweight postmenopausal women Cite
  Kjartansdottir OJ, Sigurdardottir LG, Olafsdottir EJ, Jonasson JG, Ursin G, Tryggvadottir L. Estrogen–progestin use and breast cancer characteristics in lean and overweight postmenopausal women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 163:363-373 10.1007/s10549-017-4171-2
• Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement Cite
  Santoro N, Braunstein GD, Butts CL, Martin KA, McDermott M, Pinkerton JV. Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement. The Journal of Clinical Endocrinology & Metabolism. The Endocrine Society; 2016; 101:1318-1343 10.1210/jc.2016-1271
• Abstract P1-16-06: Luteolin inhibits progestin-dependent VEGF induction, stem-cell like characteristics, and tumor progression of human breast cancer cells Cite
  Hyder S, Cook M, Besch-Williford C, Liang Y. Abstract P1-16-06: Luteolin inhibits progestin-dependent VEGF induction, stem-cell like characteristics, and tumor progression of human breast cancer cells. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p1-16-06
• Postmenopausal Female Hormone Use and Estrogen Receptor–Positive and –Negative Breast Cancer in African American Women Cite
  Rosenberg L, Bethea TN, Viscidi E, Hong C, Troester MA, Bandera EV, et al. Postmenopausal Female Hormone Use and Estrogen Receptor–Positive and –Negative Breast Cancer in African American Women. Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 108:djv361 10.1093/jnci/djv361
• Abstract 4159: Therapeutic effects of luteolin against progestin-dependent breast cancer involves induction of apoptosis, and suppression of both stem-cell-like cells and angiogenesis Cite
  Cook MT, Liang Y, Goyette S, Mafuvadze B, Besch-Williford C, Hyder S. Abstract 4159: Therapeutic effects of luteolin against progestin-dependent breast cancer involves induction of apoptosis, and suppression of both stem-cell-like cells and angiogenesis. Tumor Biology. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-4159
• Abstract 866: The proportion of breast and gynecological cancers in Australian women that can be attributed to the use of oral contraceptives and hormone replacement therapy Cite
  Jordan SJ, Wilson L, Whiteman D, Webb P. Abstract 866: The proportion of breast and gynecological cancers in Australian women that can be attributed to the use of oral contraceptives and hormone replacement therapy. Epidemiology. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-866
• Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells Cite
  Ruan X, Neubauer H, Yang Y, Schneck H, Schultz S, Fehm T, et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric. Informa UK Limited; 2012; 15:467-472 10.3109/13697137.2011.648232
• Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen Cite
  Kesim MD, Aydin Y, Atis A, Mandiraci G. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric. Informa UK Limited; 2008; 11:252-257 10.1080/13697130802163168
• Cancer Risk in Women Using the Levonorgestrel-Releasing Intrauterine System in Finland Cite
  Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Cancer Risk in Women Using the Levonorgestrel-Releasing Intrauterine System in Finland. Obstetrics & Gynecology. Ovid Technologies (Wolters Kluwer Health); 2014; 124:292-299 10.1097/aog.0000000000000356
• Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study Cite
  Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Joensuu H, et al. Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study. Acta Oncologica. Informa UK Limited; 2015; 55:188-192 10.3109/0284186x.2015.1062538
• Breast Cancer Cell Apoptosis with Phytoestrogens Is Dependent on an Estrogen-Deprived State Cite
  Obiorah IE, Fan P, Jordan VC. Breast Cancer Cell Apoptosis with Phytoestrogens Is Dependent on an Estrogen-Deprived State. Cancer Prevention Research. American Association for Cancer Research (AACR); 2014; 7:939-949 10.1158/1940-6207.capr-14-0061
• Effects of Dietary Apigenin on Tumor Latency, Incidence and Multiplicity in a Medroxyprogesterone Acetate- Accelerated 7,12-Dimethylbenz(a)anthracene- Induced Breast Cancer Model Cite
  Mafuvadze B, Cook M, Xu Z, Besch-Williford CL, Hyder SM. Effects of Dietary Apigenin on Tumor Latency, Incidence and Multiplicity in a Medroxyprogesterone Acetate- Accelerated 7,12-Dimethylbenz(a)anthracene- Induced Breast Cancer Model. Nutrition and Cancer. Informa UK Limited; 2013; 65:1184-1191 10.1080/01635581.2013.833637
• Sex Hormone Levels and Risk of Breast Cancer With Estrogen Plus Progestin Cite
  Farhat GN, Parimi N, Chlebowski RT, Manson JE, Anderson G, Huang AJ, et al. Sex Hormone Levels and Risk of Breast Cancer With Estrogen Plus Progestin. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 105:1496-1503 10.1093/jnci/djt243
• Levonorgestrel Intrauterine System in Adjuvant Tamoxifen Treatment Cite
  Gizzo S, Di Gangi S, Bertocco A, Noventa M, Fagherazzi S, Ancona E, et al. Levonorgestrel Intrauterine System in Adjuvant Tamoxifen Treatment. Reproductive Sciences. Springer Science and Business Media LLC; 2013; 21:423-431 10.1177/1933719113503408
• Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women’s Health Initiative Observational Study Cite
  Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, et al. Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women’s Health Initiative Observational Study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 105:526-535 10.1093/jnci/djt043
• Progesterone-Inducible Cytokeratin 5-Positive Cells in Luminal Breast Cancer Exhibit Progenitor Properties Cite
  Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, LaBarbera DV, et al. Progesterone-Inducible Cytokeratin 5-Positive Cells in Luminal Breast Cancer Exhibit Progenitor Properties. Hormones and Cancer. Springer Science and Business Media LLC; 2012; 4:36-49 10.1007/s12672-012-0127-5
• Progestin drives breast cancer growth by inducing p21CIP1 expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2 Cite
  Diaz Flaqué MC, Vicario R, Proietti CJ, Izzo F, Schillaci R, Elizalde PV. Progestin drives breast cancer growth by inducing p21CIP1 expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2. Steroids. Elsevier BV; 2013; 78:559-567 10.1016/j.steroids.2012.11.003
• Apigenin Induces Apoptosis and Blocks Growth of Medroxyprogesterone Acetate-Dependent BT-474 Xenograft Tumors Cite
  Mafuvadze B, Liang Y, Besch-Williford C, Zhang X, Hyder SM. Apigenin Induces Apoptosis and Blocks Growth of Medroxyprogesterone Acetate-Dependent BT-474 Xenograft Tumors. Hormones and Cancer. Springer Science and Business Media LLC; 2012; 3:160-171 10.1007/s12672-012-0114-x
• Effect of Depo-Medroxyprogesterone Acetate on Breast Cancer Risk among Women 20 to 44 Years of Age Cite
  Li CI, Beaber EF, Chen Tang MT, Porter PL, Daling JR, Malone KE. Effect of Depo-Medroxyprogesterone Acetate on Breast Cancer Risk among Women 20 to 44 Years of Age. Cancer Research. American Association for Cancer Research (AACR); 2012; 72:2028-2035 10.1158/0008-5472.can-11-4064
• Use of the levonorgestrel-releasing intrauterine system in breast cancer patients Cite
  Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertility and Sterility. Elsevier BV; 2008; 90:17-22 10.1016/j.fertnstert.2007.05.033
• Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms Cite
  Geller SE, Shulman LP, van Breemen RB, Banuvar S, Zhou Y, Epstein G, et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms. Menopause. Ovid Technologies (Wolters Kluwer Health); 2009; 16:1156-1166 10.1097/gme.0b013e3181ace49b
• Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women’s health initiative clinical trials Cite
  Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson G, et al. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women’s health initiative clinical trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 132:275-285 10.1007/s10549-011-1848-9
• Apigenin Prevents Development of Medroxyprogesterone Acetate-Accelerated 7,12-Dimethylbenz(a)anthracene-Induced Mammary Tumors in Sprague–Dawley Rats Cite
  Mafuvadze B, Benakanakere I, López Pérez FR, Besch-Williford C, Ellersieck MR, Hyder SM. Apigenin Prevents Development of Medroxyprogesterone Acetate-Accelerated 7,12-Dimethylbenz(a)anthracene-Induced Mammary Tumors in Sprague–Dawley Rats. Cancer Prevention Research. American Association for Cancer Research (AACR); 2011; 4:1316-1324 10.1158/1940-6207.capr-10-0382
• Abstract B99: Hot flashes, hormone therapy, and breast cancer risk: The Women's Health Initiative Clinical Trials Cite
  Farhat GN, LaCroix A, Grady D, Chlebowski R, Vitolins M, Manson J, et al. Abstract B99: Hot flashes, hormone therapy, and breast cancer risk: The Women's Health Initiative Clinical Trials. Epidemiology and Lifestyle Factors. American Association for Cancer Research; 2010; 10.1158/1940-6207.prev-10-b99
• Oral Contraceptive Use and Breast Cancer: A Prospective Study of Young Women Cite
  Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W, et al. Oral Contraceptive Use and Breast Cancer: A Prospective Study of Young Women. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:2496-2502 10.1158/1055-9965.epi-10-0747
• Breast Cancer Incidence and Hormone Replacement Therapy in Canada Cite
  De P, Neutel CI, Olivotto I, Morrison H. Breast Cancer Incidence and Hormone Replacement Therapy in Canada. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2010; 102:1489-1495 10.1093/jnci/djq345
• Breast Cancer Risk by Breast Density, Menopause, and Postmenopausal Hormone Therapy Use Cite
  Kerlikowske K, Cook AJ, Buist DS, Cummings SR, Vachon C, Vacek P, et al. Breast Cancer Risk by Breast Density, Menopause, and Postmenopausal Hormone Therapy Use. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:3830-3837 10.1200/jco.2009.26.4770
• Abstract 5741: Change in mammographic density with estrogen and progestin therapy: A measure of breast cancer risk in the Women's Health Initiative Cite
  Byrne C, Ursin G, Martin CF, Peck JD, Cole EB, Heiss G, et al. Abstract 5741: Change in mammographic density with estrogen and progestin therapy: A measure of breast cancer risk in the Women's Health Initiative. Epidemiology. American Association for Cancer Research; 2010; 10.1158/1538-7445.am10-5741
• Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition Cite
  Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, et al. Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer. Wiley; 2010; 128:144-156 10.1002/ijc.25314
• Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk Cite
  Shantakumar S, Terry MB, Paykin A, Teitelbaum SL, Britton JA, Moorman PG, et al. Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk. American Journal of Epidemiology. Oxford University Press (OUP); 2007; 165:1187-1198 10.1093/aje/kwm006
• Curcumin delays development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors Cite
  Carroll CE, Benakanakere I, Besch-Williford C, Ellersieck MR, Hyder SM. Curcumin delays development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors. Menopause. Ovid Technologies (Wolters Kluwer Health); 2010; 17:178-184 10.1097/gme.0b013e3181afcce5
• Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status: The Multiethnic Cohort Study Cite
  Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status: The Multiethnic Cohort Study. American Journal of Epidemiology. Oxford University Press (OUP); 2009; 169:1251-1259 10.1093/aje/kwp036